<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03455426</url>
  </required_header>
  <id_info>
    <org_study_id>IUI-letrozole/natural cycle</org_study_id>
    <nct_id>NCT03455426</nct_id>
  </id_info>
  <brief_title>Intrauterine Insemination With Letrozole Versus in Natural Cycle</brief_title>
  <official_title>Intrauterine Insemination With Letrozole Versus Intrauterine Insemination in Natural Cycle. A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Intrauterine insemination (IUI) is the treatment of first choice for couples with
      unexplained and mild male factor infertility in many countries, but it is controversial
      whether ovarian stimulation improves fertility outcomes. In recent retrospectively collected
      data, investigators found that in couples with unexplained and mild male factor infertility
      undergoing IUI, ovarian stimulation with letrozole increased live birth rate as compared to
      natural cycle IUI without substantially increasing the multiple pregnancy rate. Investigators
      therefore perform a randomized clinical trial (RCT) on the subject in the Centre of
      Reproductive Medicine, Peking University Third Hospital, Beijing, China.

      Objective: To test the hypothesis that in couples with unexplained or mild male factor
      infertility scheduled for an IUI program ovarian stimulation with letrozole increases the
      live birth rate as compared to natural cycle treatment.

      Study design Randomized clinical trial.

      Study population Women diagnosed with unexplained or mild male factor infertility scheduled
      for treatment with IUI.

      Intervention Women will be randomized for ovarian stimulation with letrozole or to natural
      cycle IUI. In the group allocated to ovarian stimulation, women will receive oral tablets
      letrozole 5 mg daily from cycle day 3-5 for 5 days. Investigators will treat the couples for
      3 cycles, with a time horizon of 4 months.

      Main study parameters/endpoints Primary outcome is ongoing pregnancy leading to live birth.
      Secondary endpoints are clinical pregnancy, multiple pregnancy, miscarriage rates, pregnancy
      complications and patients' costs.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness The strategies compared are already broadly applied in current practice. No
      additional risks are expected. There is no benefit for participants, but the results may
      benefit future subfertile couples.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ongoing pregnancy</measure>
    <time_frame>3 months</time_frame>
    <description>Primary outcome is ongoing pregnancy leading to live birth</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility</condition>
  <condition>Intrauterine Insemination</condition>
  <arm_group>
    <arm_group_label>letrozole group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>letrozole 5mg/day starting from day 3 of menstrual cycle for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>natural cycle group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>Women will be randomizedfor ovarian stimulation with letrozole or to natural cycle IUI.</description>
    <arm_group_label>letrozole group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Being diagnosed with unexplained or mild male subfertility

          -  At least one sided tubal patency, established according to local protocol

          -  Normal or mild impairment of semen quality defined as a TMSC of 3 million or more
             based on at least one semen analysis

        Exclusion Criteria:

          -  Woman with dDouble sided tubal pathology

          -  Women with irregular cycles, PCOS or other endocrine disorders

          -  Impaired semen quality: pre-wash TMSC &lt;3 million.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuo Huang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuo Huang, PhD</last_name>
    <phone>86-13601203410</phone>
    <email>homelyleaf@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Qiao, MD, PHD</last_name>
      <phone>86-10-82266699</phone>
    </contact>
    <investigator>
      <last_name>Jie Qiao, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 25, 2018</study_first_submitted>
  <study_first_submitted_qc>March 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>July 4, 2019</last_update_submitted>
  <last_update_submitted_qc>July 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Third Hospital</investigator_affiliation>
    <investigator_full_name>Jie Qiao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT03455426/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

